Athira Pharma, Inc. (NASDAQ:LONA) Given Average Recommendation of “Hold” by Brokerages

Posted by Francis Steltz on Jul 23rd, 2026

Shares of Athira Pharma, Inc. (NASDAQ:LONA – Get Free Report) have received an average recommendation of “Hold” from the five brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $15.00.

Several brokerages have recently commented on LONA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a report on Monday, May 11th. Piper Sandler assumed coverage on Athira Pharma in a research note on Wednesday, May 27th. They issued an “overweight” rating and a $20.00 price target for the company. Finally, Wall Street Zen raised Athira Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th.

Check Out Our Latest Stock Analysis on Athira Pharma

Athira Pharma Stock Performance

LONA stock opened at $7.56 on Thursday. Athira Pharma has a 52 week low of $3.24 and a 52 week high of $14.21. The company has a market capitalization of $70.99 million, a PE ratio of -1.45 and a beta of 2.01. The company’s 50-day simple moving average is $8.84 and its 200 day simple moving average is $8.09.

Athira Pharma (NASDAQ:LONA – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.73) earnings per share for the quarter. On average, analysts forecast that Athira Pharma will post -3.12 EPS for the current year.

Institutional Trading of Athira Pharma

A number of institutional investors have recently modified their holdings of LONA. Focus Partners Wealth bought a new position in shares of Athira Pharma in the third quarter worth $35,000. Jane Street Group LLC bought a new stake in Athira Pharma during the fourth quarter worth about $100,000. Renaissance Technologies LLC grew its stake in Athira Pharma by 44.7% during the fourth quarter. Renaissance Technologies LLC now owns 75,147 shares of the company’s stock worth $569,000 after buying an additional 23,223 shares in the last quarter. Seven Fleet Capital Management LP acquired a new stake in Athira Pharma during the fourth quarter worth about $969,000. Finally, Millennium Management LLC acquired a new stake in Athira Pharma during the fourth quarter worth about $2,456,000. 57.12% of the stock is currently owned by institutional investors.

Athira Pharma Company Profile

(Get Free Report)

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.